Brian Plato, DO
Neurology · Louisville, KYNPI 1285821876
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $192,457 of the $231,545 with a category attached, or 83.1%. 12 manufacturers reported payments, led by Amgen at 54.9% of the total. Reporting peaked in 2019 at $100,678 and has fallen 99.9% since, to $91 in 2024. Among neurology clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 426 payments — averaging $543.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$127K
- AbbVie$57K
- Lilly USA, LLC$31K
- Biohaven Pharmaceuticals, Inc.$9K
- Teva Pharmaceuticals USA, Inc.$3K
- Biohaven Pharmaceutical Holding Company Ltd.$3K
- plus $398 from 6 others
Across 17 payments — averaging $2064.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$19K
- Teva Pharmaceuticals USA, Inc.$8K
- Avanir Pharmaceuticals, Inc.$8K
What the payments were for
- Consulting fees$24,64511%
- Speaking & faculty fees$192,45783%
- Travel & lodging$7,5123%
- Food & beverage$6,9233%
- Education$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 119 | $127,027 |
| AbbVie(2 entities) | 179 | $57,349 |
| Lilly USA, LLC | 87 | $31,185 |
| Biohaven Pharmaceuticals, Inc. | 10 | $9,221 |
| Teva Pharmaceuticals USA, Inc. | 7 | $3,306 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $3,060 |
| Sunovion Pharmaceuticals Inc. | 9 | $170 |
| Novartis | 7 | $106 |
| Pfizer | 1 | $70 |
| Currax Pharmaceuticals LLC | 2 | $26 |
| Supernus Pharmaceuticals, Inc. | 1 | $13 |
| Assertio Therapeutics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$231,545 in reported general payments places this provider in the 95th percentile of 210 neurology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aimovig AutoinjectorErenumab-Aooe | 233 | $214,205 |
| UbrelvyUbrogepant | 168 | $183,442 |
| Emgality PenGalcanezumab-Gnlm | 151 | $124,429 |
| Nurtec OdtRimegepant Sulfate | 96 | $107,351 |
| QuliptaAtogepant | 51 | $62,201 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 61 | $49,470 |
| Ajovy SyringeFremanezumab-Vfrm | 41 | $31,920 |
| Sumatriptan Succinate | 259 | $24,291 |
| Emgality SyringeGalcanezumab-Gnlm | 13 | $23,474 |
| Lacosamide | 103 | $11,098 |
| ReyvowLasmiditan Succinate | 14 | $10,061 |
| Oxcarbazepine | 79 | $8,321 |
| Gabapentin | 537 | $7,457 |
| Butalb-Acetaminoph-Caff-CodeinButalbit/Acetamin/Caff/Codeine | 28 | $4,064 |
| RizatriptanRizatriptan Benzoate | 191 | $3,254 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta | $57,349 | $245,643219 claims |
| PfizerNurtec Odt | $70 | $107,35196 claims |
| Lilly USA, LLCReyvow | $31,185 | $10,06114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 210 neurology providers in Kentucky.
Other neurology in Louisville
- Kristi NordLouisville$217K
- Angela HardwickLouisville$187K
- Peter HederaLouisville$185K
- Jeffrey FrankLouisville$181K
- Mohammad AlsorogiLouisville$111K
- Tad SeifertLouisville$99K
- Michael SweeneyLouisville$71K
- Michael SowellLouisville$60K
- David RobertsonLouisville$58K
- Jenny FengLouisville$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.